Nexalin Technology Inc. 宣布,基于2026年第二季度举行的战略会议成果,公司计划向美国食品药品监督管理局(FDA)提交一份修订版的Q-Submission申请。
Nexalin Technology Inc. 宣布,基于2026年第二季度举行的战略会议成果,公司计划向美国食品药品监督管理局(FDA)提交一份修订版的Q-Submission申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.